



Balfour Capital Group Amgen Inc.

Amgen Inc., founded in 1980 and headquartered in Thousand Oaks, California, is a leading biotechnology company. It specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. The company's mission is to serve patients by transforming the promise of science and biotechnology into therapies that restore health or save lives. Amgen focuses on areas with high unmet medical needs, including oncology, cardiovascular disease, inflammation, nephrology, and bone health.

1. Top 5 Competitors

Amgen operates in a competitive biopharmaceutical landscape. Its top five competitors include:

- Roche (Genentech)
- Novartis
- Pfizer
- Johnson & Johnson (Janssen Biotech)
- Merck & Co.

These companies compete with Amgen across various therapeutic areas and invest heavily in research and development.

2. Largest Institutional Shareholders

As of the latest data, the largest institutional shareholders of Amgen are:

- The Vanguard Group, Inc. – 9.7% ownership
- BlackRock Advisors LLC – 6.3% ownership
- State Street Corporation – 5.5% ownership

These institutions collectively hold a significant portion of Amgen's outstanding shares.

3. Management Team

Amgen's leadership comprises experienced professionals guiding the company's strategic direction:

- Robert A. Bradway – Chairman and Chief Executive Officer
- James Bradner, M.D. – Executive Vice President, Research and Development
- Murdo Gordon – Executive Vice President, Global Commercial Operations
- Esteban Santos – Executive Vice President, Operations
- David M. Reese, M.D. – Executive Vice President, Chief Technology Officer
- Susan Sweeney – Executive Vice President, Obesity and Related Conditions
- Paul Burton, M.D. – Senior Vice President and Chief Medical Officer

This team is responsible for driving innovation and operational excellence across Amgen's global operations.



Balfour Capital Group Amgen Inc.

4. Revenue

In the fiscal year 2024, Amgen reported total revenues of \$33.4 billion, marking a 19% increase compared to the previous year. This growth was primarily driven by a 23% increase in product sales volume.

For the first quarter of 2025, Amgen reported revenues of \$8.1 billion, a 9% increase year-over-year. The company projects full-year 2025 revenues between \$34.3 billion and \$35.7 billion.

5. Institutions with Buy Recommendations:

Several financial institutions have issued buy recommendations for Amgen's stock:

- Cantor Fitzgerald initiated coverage with an "Overweight" rating, indicating a positive outlook on the stock's performance.
- Argus Research maintained a "Buy" recommendation, reflecting confidence in Amgen's growth prospects.

6. Analyst Sentiment Summary

Analyst sentiment towards Amgen is generally positive:

- Out of 35 analysts, 29% recommend a "Strong Buy," 29% a "Buy," 31% suggest "Hold," 9% advise "Sell," and 3% recommend a "Strong Sell."

The average one-year price target is \$328.48, with forecasts ranging from \$186.85 to \$420.00.

7. Insider Buying and Selling (Last 24 Months)

Over the past 24 months, Amgen insiders have engaged in the following transactions:

- Shares Bought: 165,848
- Shares Sold: 326,906

Notably, key executives such as David M. Reese, Jonathan P. Graham, Murdo Gordon, and Nancy A. Grygiel have sold shares totaling approximately \$27.1 million.